Prognostic value of molecular subtypes, Ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 5, 2012, Pages 1123-1132

  Selz, Jessica ^a   Stevens, Denise ^a   Jouanneau, Ludivine ^a   Labib, Alain ^a   Le Scodan, Romuald ^b  

^a INSTITUT CURIE   (France)

^b Centre hospitalier prive Saint Gregoire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; COX ANALYSIS; HAZARD RATIO; LOCOREGIONAL CONTROL; LOCOREGIONAL RECURRENCE; LYMPH NODE; OVERALL SURVIVAL; POSTMASTECTOMY RADIATION THERAPIES; POSTMASTECTOMY RADIOTHERAPY; PROGNOSTIC FACTORS; PROSPECTIVE STUDY; RADICAL MASTECTOMY;

BODY FLUIDS; FACTOR ANALYSIS; MULTIVARIANT ANALYSIS; RADIOTHERAPY; TUMORS;

DISEASES;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMASTECTOMY RADIOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPH NODES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 84869135431     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.02.047     Document Type: Article

References (24)

1. A. Recht, S.B. Edge, and L.J. Solin Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 2001 1539 1569
2. M. Clarke, R. Collins, and S. Darby Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2005 2087 2106
3. N.P. Rowell Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review Radiother Oncol 91 2009 23 32
4. T. Sorlie, R. Tibshirani, and J. Parker Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 2003 8418 8423
5. M.C. Cheang, D. Voduc, and C. Bajdik Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 2008 1368 1376
6. L.A. Carey, C.M. Perou, and C.A. Livasy Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2006 2492 2502
7. B.S. Abdulkarim, J. Cuartero, and J. Hanson Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy J Clin Oncol 29 2011 2852 2858
8. J.M. Albert, A.M. Gonzalez-Angulo, and M. Guray Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer Int J Radiat Oncol Biol Phys 77 2010 1296 1302
9. R. Dent, M. Trudeau, and K.I. Pritchard Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 2007 4429 4434
10. B.G. Haffty, Q. Yang, and M. Reiss Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 2006 5652 5657
11. M. Kyndi, F.B. Sorensen, and H. Knudsen Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group J Clin Oncol 26 2008 1419 1426
12. E.K. Millar, P.H. Graham, and S.A. O'Toole Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel J Clin Oncol 27 2009 4701 4708
13. P.L. Nguyen, A.G. Taghian, and M.S. Katz Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 2008 2373 2378
14. K.D. Voduc, M.C. Cheang, and S. Tyldesley Breast cancer subtypes and the risk of local and regional relapse J Clin Oncol 28 2010 1684 1691
15. S.L. Wang, Y.X. Li, and Y.W. Song Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy Int J Radiat Oncol Biol Phys 80 2011 1095 1101
16. N.D. Arvold, A.G. Taghian, and A. Niemierko Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy J Clin Oncol 29 2011 3885 3891
17. Frédérique Penault-Llorca, Fabrice André, and Christine Sagan Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2009 2809 2815
18. E. Yildirim, and U. Berberoglu Can a subgroup of node-negative breast carcinoma patients with T1-2 tumor who may benefit from postmastectomy radiotherapy be identified? Int J Radiat Oncol Biol Phys 68 2007 1024 1029
19. P.T. Truong, M. Lesperance, and A. Culhaci Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy Int J Radiat Oncol Biol Phys 62 2005 175 182
20. E.P. Mamounas, G. Tang, and B. Fisher Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20 J Clin Oncol 28 2010 1677 1683
21. R. Yerushalmi, R. Woods, and P.M. Ravdin Ki67 in breast cancer: prognostic and predictive potential Lancet Oncol 11 2010 174 183
22. R. Stuart-Harris, C. Caldas, and S.E. Pinder Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients Breast 17 2008 323 334
23. N. Hollander, W. Sauerbrei, and M. Schumacher Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint Stat Med 23 2004 1701 1713
24. M. Dowsett, T.O. Nielsen, and R. A'Hern Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group JNCI J Natl Cancer Inst 22 2011 1656 1664